Discover Great Companies Discover Great Clients
Companies Salaries Jobs
Jobs |
Jobs Companies Salary Majors

Company Overview

Development Stage

About the Company

[Summary] 肿瘤靶标小分子创新药物研发商

公司成立于2018年12月,由中科院“百人计划”教授朱继东博士共同创办,专注开发具有显著差异化和创新性的小分子药物。创始人拥有将研发成果商业化,成果转让给大型药企的成功经验,金额达数亿美元。
核心团队成员来自诺华、艾伯维、赛诺菲等跨国药企,人均具有10年以上的药物研发经验,累计专利20篇以上,5个以上研发药物进入临床和临床前阶段。公司40的员工拥有博士学位,70的员工拥有硕士及以上学位。
奕拓专注于开发当前认为“undruggable”(不可靶向)靶点的抗肿瘤小分子药物。在成立不到两年的时间内,奕拓自主开发了全球创新的药物开发平台,打造了七个研发管线,其中两个产品今年推进临床,为治疗肿瘤提供新的解决方案。

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

奕拓医药 Financing History (6 rounds)

Manage
B++轮
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Amount: 融资金额未公开
  • Investor: 广州金控集团

奕拓医药 honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

奕拓医药 Related Industry Tags

Tags are auto-annotated by keyword text matching and may be correlated. For reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 2,500万(美元)
Legal Representative: 朱继东
Date Established:
Credit Code: 91310115MA1K48MC9B
Registered Address: 中国(上海)自由贸易试验区蔡伦路720弄5号2.15单元

People who follow 奕拓医药 also follow

奕拓医药 Competitors (Similar Companies)

“抗癌新药研发商”
生物科技 生物科技/生物工程

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates

室内娱乐
客服
由百度提供